TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34073610
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g daily of bitter and strong-tasting (BST) vegetables
Study: 34073610
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g daily of mild and sweet-tasting (MST) vegetables
Study: 34073610
Drug: 120 g
Normalized name: soap 120 gram TOPICAL BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 g daily MST normal diet (control)
Study: 36113110
Drug: Nonsupervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsupervised physical activity (30 min of self-administered physical aerobic activity daily for 2 weeks before and 4 weeks after surgery)
Study: 36113110
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy subgroup
Study: 32314505
Drug: 2.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg/kg GLP-1-gFc
Study: 32314505
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg dulaglutide
Study: 32314505
Drug: 0.28 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.28 mg/kg GLP-1-gFc
Study: 32314505
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg dulaglutide
Study: 32648641
Drug: Peanut protein
Normalized name: peanut protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut protein ingestion (300-1000 mg)
Study: 32404169
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera 3% topical ointment
Study: 35569763
Drug: 1-mg intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mg intravitreal risuteganib injection
Study: 32708396
Drug: exercise routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: exercise routine combined with intake of 2 g/day oil from Calanus finmarchicus (EXCO)
Study: 35124144
Drug: Ethanol-based (WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol-based (WHO gel formulation)
Study: 35124144
Drug: Ethanol-based with
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol-based with superfatting agents (Saniswiss Sanitizer Hands H1)
Study: 35177467
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (relevant lifestyle advice and cardio‐preventive medication)
Study: 32521284
Drug: Vibration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration therapy (10 self-applied sessions)
Study: 34960106
Drug: Liposomal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal formulation of vitamin A
Study: 32481287
Drug: Dan-Hong Hua-Yu
Normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dan-Hong Hua-Yu oral solution
Study: 35466808
Drug: Standard hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hydrocolloid gel dressings (HG)
Study: 35238798
Drug: HIIE +
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIE + MLT (3 mg)
Study: 34688568
Drug: Corticision-assisted orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticision-assisted orthodontic treatment (CORT); n=26 (6 males, 20 females, mean age 21.30)
Study: 34688568
Drug: Traditional orthodontic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional orthodontic treatment (TRAD); n=26 (8 males, 18 females, mean age 21.46)
Study: 34688568
Drug: Corticision-assisted orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticision-assisted orthodontic treatment (CORT)
Study: 34688568
Drug: Traditional orthodontic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional orthodontic treatment (TRAD)
Study: 34364917
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 μg/kg daily for the first 5 days and every third day thereafter until day 26) plus standard medical therapy (SMT)
Study: 34364917
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 μg/kg daily for the first 5 days and every third day thereafter until day 26) plus SMT
Study: 33444874
Drug: Fluency shaping
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluency shaping treatment (soft voice onsets)
Study: 32736893
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day for 7 days
Study: 32736893
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/day for 7 days
Study: 32620144
Drug: Ultra-short-wave diathermy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-short-wave diathermy treatment + nationally recommended standard medical treatment
Study: 32620144
Drug: Nationally recommended
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nationally recommended standard medical treatment
Study: 35662337
Drug: Mezlocillin 50
Normalized name: Mezlocilline
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mezlocillin 50 mg/kg q12h
Study: 35662337
Drug: Mezlocillin 20
Normalized name: mezlocillin 20 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin 20 mg/kg q8h
Study: 36462182
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (high-dose vitamin D3)
Study: 36462182
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (high-dose vitamin D3) in those taking antidepressants at baseline
Study: 36462182
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (high-dose vitamin D3) in participants with predicted 25(OH)D concentration <50 nmol/L
Study: 36462182
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (high-dose vitamin D3) in participants with predicted 25(OH)D ≥50 nmol/L
Study: 32900220
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment (cognitive behavioural treatment and motivational enhancement)
Study: 32900220
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (alcohol-focused treatment)
Study: 32900220
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Integrated and Control)
Study: 33725772
Drug: Antiviral medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiviral medications
Study: 35788739
Drug: Inhaled ginger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ginger essential oil
Study: 35788739
Drug: Inhaled German
Normalized name: German cockroach allergenic extract
DrugBank: Blatella germanica (DB10418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled German chamomile essential oil
Study: 35788739
Drug: Inhaled bergamot
Normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bergamot essential oil
Study: 35638561
Drug: CJM112 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJM112 300 mg (anti-IL-17A IgG1/κ monoclonal antibody)
Study: 36467553
Drug: Zaoren Anshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaoren Anshen capsule and 5 mg zolpidem tartrate (Group ZA + Z5)
Study: 36467553
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zolpidem tartrate (Group Z10)
Study: 36467553
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zolpidem tartrate and placebo capsule (Group Z5)
Study: 36467553
Drug: Zaoren Anshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaoren Anshen capsule and placebo pill (Group ZA)
Study: 34052844
Drug: Probiotic compounds
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic compounds (4 strains; Lactobacillus plantarum MH‐301, L. rhamnosus LGG‐18, L. acidophilus, Bifidobacterium animalis subsp.lactis LPL‐RH)
Study: 34052844
Drug: Probiotic compounds
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic compounds administration in rat models
Study: 32386395
Drug: THC (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (7.5 and/or 15 mg oral)
Study: 39689109
Drug: Horticultural Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural Therapy (HT)
Study: 35460517
Drug: Self-management intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management intervention for lung cancer surgery preparation/recovery
Study: 33038967
Drug: Subcutaneous vosoritide
Normalized name: vosoritide
DrugBank: Vosoritide (DB11928)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous vosoritide therapy
Study: 33864354
Drug: Magnesium +
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium + Vitamin B6 (Magne B6®; daily dose 300 mg magnesium and 30 mg vitamin B6)
Study: 33864354
Drug: Magnesium alone
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium alone (Magnespasmyl®; daily dose 300 mg)
Study: 32372561
Drug: Local methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local methylcobalamin injection and lidocaine (LM group)
Study: 32372561
Drug: Intramuscular methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular methylcobalamin and local lidocaine (IM group)
Study: 32372561
Drug: Oral methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylcobalamin tablet and lidocaine local injection (OM group)
Study: 33959583
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (CG)
Study: 33137599
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg three times daily)
Study: 32949370
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Brivaracetam (BRV) 100 mg post-5-min intravenous infusion
Study: 32949370
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Brivaracetam (BRV) 1500 mg post-15-min intravenous infusion
Study: 32949370
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1500 mg post-15-min intravenous infusion
Study: 32949370
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1500 mg post-5-min intravenous infusion
Study: 35090638
Drug: 5 7mu;g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 7mu;g CoV2 preS dTM with AS03
Study: 35090638
Drug: 10 7mu;g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 7mu;g CoV2 preS dTM with AS03
Study: 35090638
Drug: 15 7mu;g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 7mu;g CoV2 preS dTM with AS03
Study: 35101085
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg daily for 6 months
Study: 34078324
Drug: Emotion-Focused Treatment
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion-Focused Treatment (EFT)
Study: 32751522
Drug: Magnesium (500
Normalized name: magnesium gluconate 27 mg magnesium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (500 mg/day)
Study: 33656950
Drug: Arthroscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic surgery with postoperative physical therapy (SPT)
Study: 33656950
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy alone (PTA)
Study: 35029879
Drug: MBSR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBSR therapy
Study: 36069630
Drug: Enriched pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched pain management (EPM) pathway integrating physical therapy and mindfulness
Study: 32703548
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (haemoglobin, 90–110 g L−1)
Study: 32703548
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (haemoglobin, 70–90 g L−1)
Study: 32985946
Drug: Caffeine (3-mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3-mg/kg bodyweight)
Study: 32985946
Drug: Placebo (3-mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3-mg/kg bodyweight lactose)
Study: 39284953
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (chemotherapy)
Study: 32469183
Drug: Relugolix (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix (120 mg orally once daily)
Study: 37713020
Drug: Leuprolide (injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (injections every 3 months)
Study: 34908015
Drug: Low-iron formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-iron formula with added bovine lactoferrin (1.0 g/L)
Study: 34908015
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula at 8 mg/L iron and no added lactoferrin (control formula)
Study: 32203968
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (50,000 IU weekly for 9 weeks)
Study: 34446483
Drug: Community-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based intervention with integrated skin screening and SDR-PEP administration
Study: 34446483
Drug: Health centre-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health centre-based intervention with integrated skin screening and SDR-PEP administration
Study: 36199771
Drug: Microwave ablation
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microwave ablation combined with anti-PD-1 monoclonal antibody
Study: 36199771
Drug: Anti-PD-1 monoclonal
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 monoclonal antibody
Study: 33607060
Drug: ACEi or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEi or ARB treatment (n=3601)
Study: 33607060
Drug: No ACEi
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACEi or ARB treatment (n=3601)
Study: 32126990
Drug: ICMA (intracameral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICMA (intracameral combination of 2 mydriatics and 1 anesthetic)
Study: 32126990
Drug: Topical regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical regimen (conventional treatment)
Study: 37028614
Drug: Silicone breast
Normalized name: Tommee Tippee Silicone Breast Pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone breast implants
Study: 34850368
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of sitagliptin phosphate/metformin hydrochloride tablets (50 mg/850 mg) under fasting conditions
Study: 34850368
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (JANUMET®) under fasting conditions
Study: 34850368
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of sitagliptin phosphate/metformin hydrochloride tablets (50 mg/850 mg) under fed conditions
Study: 34850368
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (JANUMET®) under fed conditions
Study: 36055332
Drug: Pegcetacoplan (1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegcetacoplan (1080 mg subcutaneously twice weekly)
Study: 36055332
Drug: Pegcetacoplan monotherapy
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegcetacoplan monotherapy
Study: 33434408
Drug: Ertugliflozin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 25 mg (Cohort B)
Study: 34762378
Drug: Acupuncture for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture for regulating spleen and stomach combined with aspirin enteric‐coated tablets
Study: 34762378
Drug: Aspirin enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin enteric‐coated tablets (100 mg once daily)
Study: 32513836
Drug: pTVG-AR vaccine
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pTVG-AR vaccine with or without GM-CSF adjuvant
Study: 32513836
Drug: pTVG-AR vaccine
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pTVG-AR vaccine
Study: 35867853
Drug: Oral tianeptine
Normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tianeptine (50 mg)
Study: 35867853
Drug: Intravenous tianeptine
Normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tianeptine (500 to 2000 ng/ml)
Study: 34843346
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure (PE) therapy, delivered in a massed format (daily sessions across 2 weeks)
Study: 36306151
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Liraglutide, Diet, Sitagliptin)
Study: 32219359
Drug: Apabetalone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apabetalone (100 mg orally twice daily)
Study: 32165032
Drug: Home-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based therapy (DVD)
Study: 36128663
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg intravenously) every 4 weeks for 24 weeks
Study: 36128663
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg intravenously)
Study: 32735952
Drug: Acute hyperglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hyperglycaemia (mean blood glucose: 321 ± 29 mg/dL)
Study: 32735952
Drug: Euglycaemia (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (mean blood glucose: 138 ± 34 mg/dL)
Study: 33428583
Drug: Durvalumab (D)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (D) 1500 mg/tremelimumab (T) 75 mg (intravenously every 4 weeks without SBRT)
Study: 33984151
Drug: Concurrent temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concurrent temozolomide and radiotherapy followed by adjuvant temozolomide
Study: 35562720
Drug: Mild anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild anemia (Hb 10.0-11.0 g/dL)
Study: 35562720
Drug: Moderate anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate anemia (Hb 7.0-10.0 g/dL)
Study: 35562720
Drug: Severe anemia
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe anemia (Hb < 7.0 g/dL)
Study: 32860075
Drug: Anti-PD1 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-PD1 therapy (discontinued due to prolonged remission or unacceptable toxicity)
Study: 32764081
Drug: Acupuncture (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (one session of Western medical acupuncture treatment in addition to standard treatment)
Study: 32764081
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment according to Norwegian guidelines
Study: 34500081
Drug: Milrinone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (0.5 ?g/kg/min)
Study: 34500081
Drug: Nitroglycerin (0.2-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.2-0.5 ?g/kg/min)
Study: 36476466
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac postoperatively and 3 days of oral ketorolac on discharge
Study: 36476466
Drug: Standard-of-care pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care pain protocol involving oxycodone-acetaminophen 5 to 325 on discharge
Study: 34895160
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose citrate (4.5 mmol/L)
Study: 34895160
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose citrate (2.5 mmol/L)
Study: 32409981
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg IV tramadol
Study: 32409981
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg IV morphine
Study: 34001407
Drug: Cryotherapy (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy (80 minutes applied in addition to standard oral care)
Study: 33072188
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (20 grams total, with a 15-minute loading dose followed by a 24-hour maintenance infusion)
Study: 33072188
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered in the same manner as magnesium sulfate)
Study: 33657760
Drug: Continuous intra‐articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intra‐articular (IA) infusion analgesia
Study: 34213086
Drug: Baseline Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline Treatment Expectancy Scale (TES)
Study: 34000325
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg.kg‐1
Study: 34000325
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 μg.kg‐1
Study: 33261915
Drug: Immediate nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate nicotine reduction condition (0.4 mg/g nicotine cigarettes)
Study: 33261915
Drug: Gradual nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual nicotine reduction condition (15.5 to 0.4 mg/g)